Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam for Prevention of TB-IRIS
NCT02060006Phase 3Unknown
- Sponsor
- Stellenbosch University
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune reconstitution inflammatory syndrome (IRIS) comparing Meloxicam with Placebo (2 arms). Primary endpoint: Incidence of Tuberculosis-Immune Reconstitution Inflammatory Syndrome at 6 months. Status: unknown.
02
Drugs
meloxicam
03
Conditions
immune reconstitution inflammatory syndrome (IRIS)
Beyond the preview
Go deeper on NCT02060006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060006.